Welcoming EC Commitment to Off-Patent Biologics Market
Workshop on biosimilars access and uptake.
The European pharmaceutical industry welcomes the initiative by the European Commission Directorate General for the Internal Market, Industry, Entrepreneurship and SMEs (DG Grow) to host on 6 October 2015, an event on access to biosimilar medicines in Europe.
The “Workshop on Access to and Uptake of Biosimilar Medicinal Products” brings together healthcare stakeholders to share their perception, perspectives and experiences with biosimilar medicines developments, following the conclusion of the Process on Corporate Responsibility in the Pharmaceutical Sector, which ran from 2011 to 2014. In addition, IMS Health presented the preliminary results of a new report on ‘The impact of biosimilar competition”.
The pharmaceutical industry believes that this forum will increase the level of understanding about the benefits of biosimilar medicines competition. At present, biosimilar medicines represent a small but growing market in the EU, but also harbour a significant potential to increase access to high quality medicines for patients, contribute to the sustainability of healthcare systems and free up resources for innovative medicines. Effective biosimilar competition is part of the solution to lower healthcare expenditure and to treat more patients.
If Europe is able to establish a sustainable market framework to stimulate biosimilar competition, patients, health care providers and payers will benefit from an increased choice of available therapies and increased patient access to existing and new therapies, which will help governments to manage their budgets.
About the issuers of this press release
The industry is represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA), the European Generic and Biosimilar medicines Association (EGA) and the European Association for Bio-industries (EuropaBio).
For further information, please contact:
EFPIA: Communications Team, +32 2626 2555, email@example.com
EBG/EGA: Doris Casares, +32 2 533 98 18, firstname.lastname@example.org
The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 33 national associations and 39 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.
About the EBG and the EGA
The European Biosimilars Group (EBG), a sector group of the EGA, represents the leading companies in the biosimilar medicines space. The EBG Members bring competition to the biologicals market, thereby increasing access to highly innovative medical treatments to patients, in Europe and around the world, and supporting the sustainability of the European healthcare systems.
The EGA represents the European generic, biosimilar and value-added medicines industries, which provide high-quality cost-competitive medicines to millions of Europeans. Companies represented within the EGA provide over 160,000 skilled, high value direct jobs in Europe. Generic medicines save EU patients and healthcare systems over €40 billion each year and account for 54% of all dispensed medicines but for only 21% of the pharmaceutical expenditure in Europe. The European generic and biosimilar medicines industries’ vision is to provide sustainable access to high quality medicines for all European patients, based on 5 important pillars: patients, quality, value, sustainability and partnership. For more information please follow EGA at www.egagenerics.com and on Twitter @egagenerics and @ebgbiosimilars.